Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Recent Pat DNA Gene Seq. 2009;3(3):201-12.

Recent patents on PCSK9: a new target for treating hypercholesterolemia.

Author information

  • 1Department of VeteransAffairs, Palo Alto Health Care System (154P), Palo Alto, CA 94304, USA. haili_65@yahoo.com

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9), the ninth member of the proprotein convertase (PC)family, has emerged as a potential target for reducing plasma low-density lipoprotein cholesterol (LDL-c) levels. PCSK9post-transcriptionally downregulates the low-density lipoprotein receptor (LDLR) in the liver by binding to the epidermalgrowth factor-like repeat A (EGF-A) domain of the LDLR and thereby controls the level of LDL-c in plasma. Some of its natural mutations called gain-of-function mutations cause hypercholesterolemia and coronary heart disease (CHD), whereas loss-of-function mutations in the PCSK9 gene are associated with hypocholesterolemia. This review summarizes the current understanding of PCSK9 and recently published patent and patent applications on methods and techniques that may efficiently reduce plasma LDL-c levels through inhibiting PCSK9 expression by antisense oligonucleotides, small interference RNAs (siRNAs), specific antibodies, or other small molecules.

PMID:
19601924
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk